Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $185.20.

Several equities research analysts have recently weighed in on RGEN shares. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, December 19th. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company.

Repligen Stock Up 0.9 %

Shares of RGEN stock opened at $146.95 on Wednesday. Repligen has a one year low of $113.50 and a one year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a fifty day moving average price of $144.23 and a 200 day moving average price of $141.65. The stock has a market cap of $8.23 billion, a P/E ratio of -397.15, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.23 EPS. Analysts predict that Repligen will post 1.54 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

A number of large investors have recently modified their holdings of RGEN. Franklin Resources Inc. raised its position in Repligen by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company’s stock worth $47,551,000 after purchasing an additional 26,668 shares during the last quarter. Peapack Gladstone Financial Corp bought a new stake in shares of Repligen during the third quarter worth $296,000. Tidal Investments LLC lifted its stake in shares of Repligen by 142.8% during the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock valued at $1,659,000 after acquiring an additional 6,558 shares during the period. Sanctuary Advisors LLC bought a new position in Repligen in the third quarter valued at about $233,000. Finally, Coldstream Capital Management Inc. increased its position in Repligen by 11.8% in the third quarter. Coldstream Capital Management Inc. now owns 2,194 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 231 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.